This study focuses on preventing chronic migraine in young people aged 12 to under 18 years. Chronic migraine is a condition where a person experiences headaches on 15 or more days per month, with at least 8 of these being migraine headaches. These migraine attacks typically last between 4 to 72 hours when left untreated and can significantly impact daily life.
The study will test a medication called rimegepant sulfate (also known as PF-07899801), which belongs to a group of medicines called calcitonin gene-related peptide antagonists. This medicine comes as an orodispersible tablet that dissolves in the mouth and is taken by mouth. The purpose is to determine if rimegepant sulfate works better than placebo in preventing migraines in adolescents with chronic migraine.
The study will last several months and will have two parts. In the first part, participants will receive either rimegepant sulfate or placebo without knowing which one they are taking. After this initial phase, there will be an extended period where all participants will receive the active medication. Throughout the study, participants will need to keep track of their headache days and complete questionnaires about how migraines affect their daily activities.
Czechia 
Finland 
Hungary 
Italy 
Poland 
Slovakia 
Spain 
